Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)
  Email:

CAR Lentiviral Packaging Service


Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s targeting tumor-associated antigens...

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

CAR Lentiviral Packaging Service

Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s targeting tumor-associated antigens can be infused into patients and attack the tumor. Chimeric Antigen Receptor (CAR) T cell therapy has shown great promise for cancer treatment.

The basic CAR structure consists of two fundamental domains: the extracellular antigen-binding domain and the intracellular signaling domain. The antigen-binding domain (scFv) commonly consisting of a variable heavy (VH) and a variable light (VL) chain, is derived from a monoclonal antibody (mAb). Common intracellular signaling domains include CD3ζ, CD28, 4-1BB and OX40.

Figure 1. Structure of a CAR

Lentiviruses are effective gene carriers leading to long-term gene expression. Lentiviral generated CAR-T cells targeting CD19 antigen have shown remarkable anti-tumor efficacy in clinical trials [1]. Creative Biogene has developed CAR lentiviral packaging service based on most advanced techniques and extensive experience. We provide you one stop service from constructing the lentivirus expression vector to manufacture high-titer lentivirus particles. With years of experience in research of lentivirus, Creative Biogene provides convenient and efficient services for CAR lentiviral packaging service which have high safety profile and high efficiency of gene delivery to virtually all cell types and whole model organisms. Besides, we offer a wide selection range of CAR lentivirus particles in stock which can save your precious time and effort of constructing the lentivirus vector and packaging virus.

Creative Biogene’s CAR lentivirus packaging service has the following features:

  1. One-stop solution: from constructing lentiviral CAR expression plasmid to lentivirus production.
  2. Offer custom construction of lentivirus expression plasmid with different promoters or tags.
  3. Produce high titer lentivirus particles suitable for CAR-T cells expression.
  4. Fast turnaround time: typically in a few of weeks to save your precious time for research.
  5. Cost-saving: provide high quality lentivirus particles with competitive price.
  6. 3rd generation lentiviral systems provide increased researcher safety.
  7. Quality control: testing on the safety, sterility, titer, purity and potency.
Target antigenCAR systemsType of tagsType of promotor
2nd generation3rd generation4th generationGFPRFPTREEF1αCMV
CD19
CD20
CD22
CD30
CD33
CD138
HER2
Mesothelin
EGFRvIII
IL-6R
NY-ESO-1
LAGE-1
CEA
cMet
GPC3

Reference:

  1. Grupp S A, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia[J]. New England Journal of Medicine, 2013, 368(16): 1509-1518.

Quick Inquiry

   Please input "biogene" as verification code.